Panel Discussion: Defining The Future Mash Treatment Landscape To Prioritize Differentiated Therapies, Optimize Combination Strategies & Establish Long-Term Standards Of Care
- Defining future standards of care across fibrosis, metabolic dysfunction and advanced disease populations to prioritize differentiated therapies, improving long-term clinical and commercial positioning
- Evaluating how combination strategies and emerging mechanisms will shape the post-Rezdiffra treatment landscape to optimize development planning, enabling stronger therapeutic differentiation and improved patient outcomes
- Identifying the clinical, regulatory and competitive factors that will determine best-in-class therapies to strengthen late-stage development strategies, improving adoption potential and long-term market success